Download our eBook to discover how you can simplify bispecific antibody development and manufacture risk mitigation strategies. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| This week's Fierce Biotech is brought to you by Lonza.
Trouble viewing? Click here. |
| Download our eBook to discover how you can accelerate bispecific antibody development
and manufacture | | Because bsAbs are commonly constructed of three or more heavy chain (HC) and light chain (LC) combinations, they are often difficult to assemble, express, and purify. Some of the main challenges encountered are:
The mis-pairing of HCs and LCs to produce homodimer bsAbs that has knock on effects through downstream processing and formulation
The inability to drive high titer while maintaining product quality attributes (PQAs) which may increase time and costs in the later purification and formulation steps | | | | | | | | Do you want to ensure timely and cost-effective delivery of high-quality bispecific antibody-based drug candidates? Download our latest eBook ‘Bispecific Antibody (bsAb) Development and Manufacture’ to discover how our specialized strategies and technologies could help you achieve your clinical development milestones. | | | | |
|
|
| ©2023 Lonza. All Rights Reserved.
Muenchensteinerstrasse 38
Basel 4002
Switzerland |
|
|
